Heron Therapeutics Stock News

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 2.56% and 1.27%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

When it comes to certain stocks to sell, being overly optimistic can become a liability. No, this is not a popular topic by any means, usually arousing anger among the investing faithful.

Within the portfolio of growth stocks, it's a good idea to scout for stocks under $10 to double your money. Exposure to several low-price stocks allows an investor to diversify the portfolio even with

Penny stocks have always fascinated investors. That's because higher-risk, lower-priced penny stocks to buy can be portfolio game-changers.

Investing in early-stage or unknown biotech stocks can be likened to investing in cryptocurrency projects. If the project developments are positive, returns can be multi-folds in a short time.

Heron addressed a key problem recently - its cash balance and cash burn. The cash raised and cost reductions have significantly extended the cash runway.

Here are the upcoming catalysts for Mirati Therapeutics, Novavax, and Heron Therapeutics.

Here are the upcoming catalysts for Mirati Therapeutics, Novavax, and Heron Therapeutics.

Heron Therapeutics (HRTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Heron Therapeutics (HRTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The average of price targets set by Wall Street analysts indicates a potential upside of 90.6% in Heron Therapeutics (HRTX). While the effectiveness of this highly sought-after metric is questionable,

Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 60.1% to settle at $7.27 on Tuesday after the company was granted US patent for an air treatment system and method. BBQ Holdings, Inc. (NAS

Gainers Verona Pharma plc (NASDAQ: VRNA) shares jumped 83.6% to $12.70 after the company announced ensifentrine met its primary endpoint and secondary endpoints in the Phase 3 ENHANCE-2 trial for CO

Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants David Szekeres – Executive Vice President, Chief Operating Officer Barry Quart

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -10% and 11.98%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?